Genmab has shared the first data on rinatabart sesutecan (Rina-S) in advanced endome | Genmab has shared the first data on ...

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

AbbVie's Elahere has been shown to reduce the risk of death in patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer by a third, reinforcing its blockbuster ...

Elahere shows consistent survival benefits in patients with folate receptor alpha-positive platinum-resistant ovarian cancer in the MIRASOL trial. Treatment with Elahere (mirvetuximab ...

Last June, AbbVie released positive topline data from the Phase II PICCOLO trial, which investigated Elahere as a single agent in heavily pre-treated platinum-sensitive ovarian cancer subjects.

In this video, Ursula A. Matulonis, MD, discusses results from the phase 3 MIRASOL trial of mirvetuximab soravtansine-gynx for patients with folate receptor alpha-positive, platinum-resistant ovarian ...

Ovarian cancer is the leading cause of death from ... Mirvetuximab soravtansine approved under the brand name ELAHERE® in the United States has received regulatory approval in adults with folate ...

Elahere (mirvetuximab soravtansine-gynx) is a prescription drug used to treat certain types of ovarian, fallopian tube, and peritoneal cancer in adults. Elahere can cause side effects that range ...

Current treatment options for platinum-resistant ovarian cancer (PROC) include AbbVie's Elahere and Roche's Avastin. Elahere, which recorded sales of $479 million in 2024, is approved for some ...

Medscape Medical News, October 11, 2024 Alert EMA Backs Approval of Elahere for Ovarian Cancer Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant ...